Following the Progression of [18F]FDG-PET PDRP Expression in Isolated Rapid Eye Movement Sleep Behavior Disorder (iRBD)

• Conditions: REM slaap gedragsstoornis; REM-sleep-behavior disorder (RBD); 10028037

• Registration Number: NL-OMON51620
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 7

Inclusion Criteria

- Age between 40 and 70 years old at the time of the first FDG PET scan
- Women, only if they are postmenopausal (> 1 year no menses).
- Written informed consent
- Capacity to understand the study
- Diagnosis of RBD according to the criteria of International Classification of
Sleep Disorders (ASDA Criteria 2005

Exclusion Criteria

* Claustrophobia
* Abuse of drugs or alcohol at present or in the past (as determined by
disclosed medical history)
* Kidney diseases with elevated levels of blood creatinine, liver diseases with
elevated levels of blood transaminases (at least 3 times as high as normal), or
an elevated blood level of gamma-GT (at least 5 times higher than normal)
* Insulin-dependent diabetes mellitus
* Hyperglycemia before the [18F]FDG-PET scan (> 7 mmol/l)
* Use of benzodiazepines during the day before the FDG-PET scan
* Structural cerebral lesion or any other neurological disease which can
interfere with the analysis of the image data (for example, a stroke in the
past)
* If subjects do not want to be informed about an unforeseen clinical finding
* Phenoconversion to manifest alpha-synucleinopathy (PD, MSA, DLB) during
REMPET2

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified